We use cookies to improve your experience with our site. | More info.

Specials

See all specials

Schizophrenia

Schizophrenia is a condition experienced by over 0.5% of the world's population at some time in their lives, and has a more debilitating impact on sufferers than most psychiatric illnesses, as well as a disproportionate societal impact. This special issue highlights the state of play and opportunities for progress in understanding, diagnosing and treating the condition.

Editorial

  • Combating schizophrenia

    Research has revealed daunting complexities in the psychiatric condition, but also new routes towards diagnosis and treatment.

    Nature 468, 133 ( )

News

Features

  • The making of a troubled mind

    Schizophrenia appears during adolescence. But where does one begin and the other end?

    Nature 468, 154-156 ( )

  • The drug deadlock

    The biology is too complicated. Pharma companies are quitting. Where are schizophrenia drugs going to come from?

    Nature 468, 158-159 ( )

Comment

  • Short-lived campaigns are not enough

    The stigma of mental illness will be reduced only if region-specific awareness initiatives become a permanent fixture of health and social services, argues Norman Sartorius.

    Nature 468, 163–165 ( )

  • Cognitive remediation therapy needs funding

    More rigorous studies should be done on the effects of a therapy that seems to improve the everyday functioning of people with schizophrenia, says Til Wykes.

    Nature 468, 165–166 ( )

Audio

  • Nature podcast

    Thomas Insel, director of the National Institute of Mental Health, and Til Wykes, psychiatrist at Kings College London, talk about the symptoms, causes and best treatments for schizophrenia.

Perspectives

  • Rethinking schizophrenia

    Thomas Insel, director of the National Institute of Mental Health, calls for schizophrenia to be emphasized as a neurodevelopmental disorder in which psychosis is a late — and potentially curable — stage.

    Nature 468, 187–193 ( )

  • The environment and schizophrenia

    Jim van Os, Gunter Kenis and Bart Rutten review our knowledge of the environmental factors that influence schizophrenia risk, and the major challenges that will be involved in teasing them out.

    Nature 468, 203–212 ( )

Most read